Publicis Health Acquires BBK Worldwide
Acquisition to expand clinical trial expertise through technology and patient centricity.
Publicis Health announced the acquisition of BBK Worldwide. BBK enables biotech and pharmaceutical customers to accelerate R&D programs, driving research forward through the integration of patient-centric services and proprietary technology, complementing Publicis Health's existing CTE capabilities.
As part of the acquisition, Publicis Health will acquire BBK Holdings, which in addition to BBK Worldwide, is the parent company of creative advertising agency 320Agency, technology company TCN® Technologies, and solution center RSG Engagement Solution Center. BBK's leadership team and organizational structure will remain in place.
Read more about the acquisition here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
